NicOx has selected DSM to manufacture the API for its potential blockbuster, Naproxcinod, which has completed its phase III trials. The API will be produced in DSM's Linz, Austria, facility. As a result of the agreement with DSM, NicOx has ended its API supply agreement with Archimica.
Reuters
Thursday 4 December 2008
DSM wins NicOx deal, Archimica loses out
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment